LENZ Therapeutics, Inc.
NASDAQ:LENZBiotechnology
Healthcare
$3.34 -6.62%
-$0.42 today
- Market cap
- $104.94M
- Beta
- 1.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.48
52W Low $5.85High $50.40
Volume 0.64M
Average 0.89M
Balance Sheet
Inspect the capital base behind the business.
Assets
$305.88M
FY 2025 · Annual
+42.1% YoYLiabilities
$21.54M
FY 2025 · Annual
+92.0% YoYEquity
$284.34M
FY 2025 · Annual
+39.3% YoYBalance Sheet
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 18.31M | 44.44M | 35.14M | 20.16M | 25.18M |
| Short-term Investments | 0 | 220.5M | 30.65M | 188.87M | 267.17M |
| Net Receivables | 0 | 0 | 0 | 0 | 2.43M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 16K | 2.2M | 1.45M | 114K | (2.43M) |
| Total Current Assets | 18.32M | 46.64M | 67.24M | 211.92M | 292.35M |
| Property, Plant & Equipment (Net) | 10K | 279K | 372K | 1.99M | 1.92M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2K | 31K | 2.76M | 1.4M | 2.54M |
| Total Non-current Assets | 12K | 310K | 3.13M | 3.39M | 4.46M |
| Total Assets | 18.34M | 46.95M | 70.38M | 215.3M | 305.88M |
| Account Payables | 460K | 4.76M | 5.71M | 4.26M | 4.17M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 347K | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 1.25M | 9.5M | 18.51M | 10.41M | 21.19M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 31.3M | 61.47M | 144.38M | 0 | 0 |
| Total Non-current Liabilities | 31.3M | 61.62M | 144.57M | 814K | 350K |
| Total Liabilities | 32.55M | 71.12M | 163.09M | 11.22M | 21.54M |
| Common Stock | 1K | 10K | 10K | 1K | 1K |
| Retained Earnings | (14.47M) | (25.28M) | (95.25M) | (145.01M) | (227.14M) |
| Accumulated OCI | 0 | (1.05M) | 6K | 196K | 242K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (14.21M) | (24.17M) | (92.71M) | 204.08M | 284.34M |
| Total Debt | 0 | 250K | 329K | 1.38M | 815K |
| Net Debt | (18.31M) | (44.19M) | (34.81M) | (18.78M) | (24.36M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $24.8M |
| Short-term Investments | $233.6M |
| Receivables | $343.0K |
| Inventory | $3.5M |
| Other Current | $6.1M |
| Total Current Assets | $268.4M |
| PP&E (Net) | $1.7M |
| Other Non-current | $2.5M |
| Total Non-current Assets | $4.2M |
| Total Assets | $272.5M |
Analysis
Selected assets total $272.5M for Latest. The largest visible component is Short-term Investments at $233.6M, about 85.7% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| SC 13G | SC 13G filing | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| 10-Q | Quarterly report | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 |
How much cash does LENZ have?
LENZ Therapeutics, Inc. (LENZ) reported $25.18M in cash and equivalents in fiscal 2025.
How much debt does LENZ carry?
LENZ Therapeutics, Inc. (LENZ) reported $815,000.00 of total debt, with net debt of -$24.36M.
Continue the stock analysis
Jump to another research area for this company.